Company news
Artelo Biosciences, Inc. news in 2024
Artelo Biosciences, Inc.'s news releases, calls and decks from 2024, newest first.
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
December 8, 2024
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
November 12, 2024
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 11, 2024
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
November 4, 2024
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
July 14, 2024
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium
July 2, 2024
Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform
July 1, 2024
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 12, 2024
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
April 22, 2024
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
March 24, 2024
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
January 7, 2024